There have been many advancements in terms of treatment and imaging modalities for patients with oligometastatic prostate cancer. Failure to understand these advancements in treatment options leads to lower quality of care delivered by clinicians treating prostate cancer patients.

There are many advances in the application of artificial intelligence (AI) in contouring and segmentation, as well as patient specific quality assurance.

There is increasing use of sentinel lymph node biopsy in gynecologic cancers but how best to integrate this information into post-operative radiation treatment recommendations is not always clear. This includes how to interpret isolated tumor cells, micrometastasis, and macrometastasis.

There is a high degree of variability in the management and even the understanding of the oligometastatic state in lung malignancies, or indeed in the context of any solid tumor.